SCHEMBL14616835

SCHEMBL14616835

CCc1nc(-c2cnc(-c3ccc4scnc4c3)[nH]2)n(CCOC)c1CC

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ RIPK2 O43353 3/20 0.41
▸ NPC1 O15118 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ WNT1 P04628 1/20 0.33
▸ GSK3B P49841 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ PTGER4 P35408 2/20 0.32
▸ TGFBR1 P36897 3/20 0.31
▸ LCK P06239 2/20 0.31
▸ KDR P35968 2/20 0.31
▸ PIM1 P11309 1/20 0.31
▸ PIM2 Q9P1W9 1/20 0.31
▸ DYRK2 Q92630 2/20 0.31
▸ MAP3K11 Q16584 2/20 0.31
▸ RIPK1 Q13546 1/20 0.30
▸ RIPK3 Q9Y572 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14616834 0.85 RIPK2 (0.44) RIPK2NPC1POLBALOX15MAPK1
SCHEMBL14576187 0.84 MAP3K11 (0.34) RIPK2NPC1POLBALOX15MAPK1
SCHEMBL14616792 0.84 RIPK2 (0.43) RIPK2NPC1POLBALOX15MAPK1
SCHEMBL14616793 0.83 RIPK2 (0.44) RIPK2NPC1POLBALOX15MAPK1
SCHEMBL14616791 0.83 RIPK2 (0.43) RIPK2NPC1POLBALOX15MAPK1
SCHEMBL14616794 0.83 RIPK2 (0.44) RIPK2NPC1POLBALOX15MAPK1
SCHEMBL14616801 0.83 RIPK2 (0.49) RIPK2NPC1RAB9APTGER4
SCHEMBL14616831 0.82 RIPK2 (0.47) RIPK2NPC1POLBALOX15MAPK1
SCHEMBL14616796 0.82 RIPK2 (0.53) RIPK2NPC1POLBALOX15MAPK1
SCHEMBL14616799 0.81 RIPK2 (0.51) RIPK2PTGER4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 RIPK2 255/4885NPC1 3623/4885POLB 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback